Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2011

Quarterly Financial Data (Unaudited) [Abstract]

Quarterly Financial Data (Unaudited)

26.    Quarterly Financial Data (Unaudited)

(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
2011			(a)				(b)
Product revenues	$	907.1	$	956.7	$	975.8	$	996.6	$	3,836.1
Unconsolidated joint business revenues	$	256.1	$	216.5	$	266.5	$	257.5	$	996.6
Other revenues	$	40.1	$	35.5	$	67.7	$	72.6	$	215.9
Total revenues	$	1,203.3	$	1,208.6	$	1,309.9	$	1,326.7	$	5,048.6
Gross Profit	$	1,100.2	$	1,108.1	$	1,186.4	$	1,187.1	$	4,581.9
Net income	$	308.8	$	304.0	$	353.7	$	300.2	$	1,266.7
Net income attributable to Biogen Idec Inc.	$	294.3	$	288.0	$	351.8	$	300.2	$	1,234.4
Basic earnings per share attributable to Biogen Idec Inc.	$	1.22	$	1.19	$	1.45	$	1.24	$	5.09
Diluted earnings per share attributable to Biogen Idec Inc.	$	1.20	$	1.18	$	1.43	$	1.22	$	5.04

(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
2010	(c)				(d)		(e)
Product revenues	$	824.2	$	859.2	$	876.9	$	909.8	$	3,470.1
Unconsolidated joint business revenues	$	254.9	$	306.4	$	258.0	$	258.0	$	1,077.3
Other revenues	$	29.7	$	47.1	$	41.0	$	51.4	$	169.1
Total revenues	$	1,108.9	$	1,212.7	$	1,175.8	$	1,219.0	$	4,716.4
Gross Profit	$	1,011.8	$	1,105.7	$	1,079.9	$	1,118.8	$	4,316.2
Net income	$	220.0	$	294.6	$	112.2	$	271.8	$	898.6
Net income attributable to Biogen Idec Inc.	$	217.4	$	293.4	$	254.1	$	240.3	$	1,005.3
Basic earnings per share attributable to Biogen Idec Inc	$	0.80	$	1.13	$	1.06	$	1.00	$	3.98
Diluted earnings per share attributable to Biogen Idec Inc	$	0.80	$	1.12	$	1.05	$	0.99	$	3.94

Full year amounts may not sum due to rounding.

(a) Our share of RITUXAN revenues from unconsolidated joint business was reduced by approximately $50.0 million in the second quarter of 2011 as a result of an accrual for estimated compensatory damages (including interest) relating to Genentech’s ongoing arbitration with Hoechst GmbH. For additional information related to this matter, please read Note 21, Litigation to these consolidated financial statements.

(b) Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2011 includes a charge to research and development expense of $36.8 million related to an upfront payment made in connection with our collaboration and license agreement entered into with Portola Pharmaceuticals, Inc.

(c) Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2010 includes a charge to acquired IPR&D of $40.0 million related to the achievement of a milestone by Biogen Idec Hemophilia, Inc. (formerly Syntonix Pharmaceuticals, Inc.).

(d) Net income and net income attributable to Biogen Idec Inc. for the third quarter of 2010 includes a charge to acquired IPR&D of $205.0 million incurred in connection with the license agreement entered into with Knopp Neurosciences Inc. (Knopp), which we consolidated as we determined that we are the primary beneficiary of the entity. The $205.0 million charge was partially offset by an attribution of $145.0 million to the noncontrolling interest.

(e) Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2010 includes charges totaling $75.2 million related to our restructuring plan announced November 3, 2010.